In addition to investing in innovative science and technology ventures, Beyond Next Ventures operates one of the largest technology-specific acceleration programs in Japan, providing support to researchers and early-stage technology ventures seeking to commercialize their businesses. One such program is "Blockbuster TOKYO," a development support program for drug discovery and medical ventures, which has been running since fiscal 2018 to accelerate commercialization, create a community, and foster an ecosystem. The program is designed to accelerate commercialization, create a community, and foster an ecosystem.
The features of this program include support for acquiring the knowledge necessary for drug discovery and medical venture businesses, support for management such as hiring human resources, support for business development through matching with investors and business companies, opportunities to use shared laboratories, support for research and development, and support for opportunities to make presentations at various venues including overseas venues. The program provides comprehensive support necessary for drug discovery and medical ventures. Past participants in this program have successfully started their own businesses or raised funds from investors. The program consists of two programs: a training program and a selection program. The training program includes seminars and lectures in January to provide participants with the latest trends in the bio-industry, an overview of entrepreneurship and venture business, practical knowledge about fundraising, and the knowledge necessary for efficient R&D and business alliances in venture companies. Seminars and lectures will be held about once a month. In the selection program, teams with more concrete business plans will receive professional support from mentors with expertise in each field, such as drug discovery (synthesis, non-clinical trials, clinical development, etc.), intellectual property, pharmaceutical affairs, finance, and marketing, as well as practical support in matching the team with the necessary human resources and in research and development, etc. In addition, the MHLW In addition, the mentor team is further enhanced by strengthening cooperation with the Ministry of Health, Labor and Welfare's Medical Venture Total Support Program (MEDISO).
Entry to the training program is open at any time, and entry to the selection program has also begun.
(Please refer to the Blockbuster TOKYO website "Application Guidelines" for detailed conditions.)
The project will support those who fall under either (1) or (2) below. The term "Drug Discovery/Medical Field" refers to the following four fields.
- Pharmaceuticals/Drug Discovery: small molecule drugs, biopharmaceuticals, vaccines, drug delivery systems, pharmaceutical raw materials, etc.
- Medical and diagnostic": gene therapy, regenerative medicine (cells, culture media, culture medium, reagents, etc.), immunotherapy, genetic diagnosis, imaging diagnosis, biomarkers, etc.
- Drug Discovery Support/Contract Services: Contract synthesis and manufacturing, contract analysis, compound library and screening, contract animal production and animal experiment services, CMO (contract manufacturing organization), CRO (contract research organization), SMO (clinical trial organization), drug discovery research support software and laboratory information systems, drug discovery IT, Computational drug discovery, etc.
- Others": Smart cell industry, bioinformatics, digital technology, etc. that are closely related to the above-mentioned fields, and peripheral technology of the above-mentioned fields that contribute to research and development, etc. in the above-mentioned fields.
(i) Those aiming to commercialize drug discovery/medical venture businesses in Tokyo through startups, etc. (e.g., researchers affiliated with research institutions such as universities and companies, aspiring entrepreneurs, and teams including such persons).
(2) Small and medium-sized enterprises (SMEs) engaged in drug discovery and medical-related businesses that have a place of business in Tokyo or intend to have a place of business in Tokyo in the future (SMEs are defined by the SME Act). (Definition of "SME" is based on the Small and Medium Business Act, as shown in the link below)
note (supplementary information) symbol https://www.chusho.meti.go.jp/faq/faq/faq01_teigi.htm#q1
Schedule (tentative)
- May 18, 2020 : Entry for the selection program starts
- June 2020∼March 2021: Implementation of training program (about once a month, applications accepted at any time)
- June 26, 2020 : Deadline for the first call for applications for the selection program
- July 17, 2020 : Second application deadline for the selection program
- September 2020∼March 2021: Implementation of selection program (seminars and study sessions, mentoring, matching, pitch practice sessions, R&D support, use of shared labs, travel to the U.S. events, etc.)
3. area of implementation
This program will be implemented using online tools and in Tokyo (e.g., in the Nihonbashi area of Chuo-ku, Tokyo).
4About Entry (Application) Entry (Application)
Register using the entry form on the Blockbuster TOKYO website.
If you have any questions, please contact the Blockbuster TOKYO Management Office.
Blockbuster TOKYO Websitehttps://www.blockbuster.tokyo
Inquiries Blockbuster TOKYO Management Office: info@blockbuster.tokyo
About Beyond Next Ventures
Beyond Next Ventures, founded in August 2014, is an independent accelerator specializing in incubation investment in technology startups. It is one of the few leading companies in this field in Japan, with abundant investment experience and an excellent track record of operations ranging from support for the commercialization of university seeds to venture investment and growth support, and has been certified as a business promoter under the START Program of the Japan Science and Technology Agency (JST) and a recipient of the NEDO's R&D Venture Support Program. The company manages the largest fund in Japan as an accelerator with a total of nearly 20 billion yen, including the first fund established in February 2015 and the second fund established in October 2018, and invests in numerous technology startups and supports their commercialization and growth. The company invests in a large number of technology startups and supports their commercialization and growth.
In addition to funding, we are also actively involved in commercialization support through the "BRAVE Acceleration Program" (URL: ). http://brave.team/BRAVE is the largest technology-focused acceleration program in Japan for academia. BRAVE is the largest technology-focused acceleration program in Japan, and its practical programs, such as its abundant experience in the JST START program, have led to tangible results.
In February 2019, the shared/wet lab "Beyond BioLAB TOKYO" (URL: ) will be established in Chuo-ku, Tokyo, as a base for providing commercialization support, including R&D, to startup companies in the life science field. http://biolab.beyondnextventures.com/), which provides an environment that promotes entrepreneurship and its rapid growth to technology startups, mainly in the medical and life science fields. From March 2019, the company will launch Co-founders, a co-founder matching platform specializing in technology seeds and researchers at universities and other institutions (URL: https://co-founders.team/) to help build strong start-up teams by providing online matching opportunities and real-life support.
| name of company | Beyond Next Ventures, Inc. |
| Establishment | August 2014 |
| Location | 1 Nihonbashi Murohon Building 1-4-3 Nihonbashi-Honcho, Chuo-ku, Tokyo |
| representative | Tsuyoshi Ito, President and Representative Director |
| uniform resouce locator | http://beyondnextventures.com |







